Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA
Reliable liquid biopsy-based tools able to accurately discriminate prostate cancer (PCa) from benign prostatic hyperplasia (BPH), when PSA is within the “gray zone” (PSA 4–10), are still urgent. We analyzed plasma samples from a cohort of 102 consecutively recruited patients with PSA levels between...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.769158/full |
| _version_ | 1829464782978154496 |
|---|---|
| author | Maurizia Mello-Grand Antonino Bruno Lidia Sacchetto Simone Cristoni Ilaria Gregnanin Alessandro Dematteis Andrea Zitella Paolo Gontero Caterina Peraldo-Neia Riccardo Ricotta Douglas M. Noonan Douglas M. Noonan Adriana Albini Giovanna Chiorino |
| author_facet | Maurizia Mello-Grand Antonino Bruno Lidia Sacchetto Simone Cristoni Ilaria Gregnanin Alessandro Dematteis Andrea Zitella Paolo Gontero Caterina Peraldo-Neia Riccardo Ricotta Douglas M. Noonan Douglas M. Noonan Adriana Albini Giovanna Chiorino |
| author_sort | Maurizia Mello-Grand |
| collection | DOAJ |
| description | Reliable liquid biopsy-based tools able to accurately discriminate prostate cancer (PCa) from benign prostatic hyperplasia (BPH), when PSA is within the “gray zone” (PSA 4–10), are still urgent. We analyzed plasma samples from a cohort of 102 consecutively recruited patients with PSA levels between 4 and 16 ng/ml, using the SANIST-Cloud Ion Mobility Metabolomic Mass Spectrometry platform, combined with the analysis of a panel of circulating microRNAs (miR). By coupling CIMS ion mobility technology with SANIST, we were able to reveal three new structures among the most differentially expressed metabolites in PCa vs. BPH. In particular, two were classified as polyunsaturated ceramide ester-like and one as polysaturated glycerol ester-like. Penalized logistic regression was applied to build a model to predict PCa, using six circulating miR, seven circulating metabolites, and demographic/clinical variables, as covariates. Four circulating metabolites, miR-5100, and age were selected by the model, and the corresponding prediction score gave an AUC of 0.76 (C.I. = 0.66–0.85). At a specified cut-off, no high-risk tumor was misclassified, and 22 out of 53 BPH were correctly identified, reducing by 40% the false positives of PSA. We developed and applied a novel, minimally invasive, liquid biopsy-based powerful tool to characterize novel metabolites and identified new potential non-invasive biomarkers to better predict PCa, when PSA is uninformative as a tool for precision medicine in genitourinary cancers. |
| first_indexed | 2024-12-13T16:43:06Z |
| format | Article |
| id | doaj.art-62a2a94d6e1142f6afb3f836b01fc657 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T16:43:06Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-62a2a94d6e1142f6afb3f836b01fc6572022-12-21T23:38:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-11-011110.3389/fonc.2021.769158769158Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSAMaurizia Mello-Grand0Antonino Bruno1Lidia Sacchetto2Simone Cristoni3Ilaria Gregnanin4Alessandro Dematteis5Andrea Zitella6Paolo Gontero7Caterina Peraldo-Neia8Riccardo Ricotta9Douglas M. Noonan10Douglas M. Noonan11Adriana Albini12Giovanna Chiorino13Cancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia, Biella, ItalyLaboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry, and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, ItalyDepartment of Mathematical Sciences, Politecnico di Torino, Torino, ItalyI.S.B.—Ion Source & Biotechnologies srl, Biotechnology, Bresso, ItalyCancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia, Biella, ItalyDepartment of Urology, San Giovanni Battista Hospital of Torino, Corso Torino, ItalyDepartment of Urology, San Giovanni Battista Hospital of Torino, Corso Torino, ItalyDepartment of Urology, San Giovanni Battista Hospital of Torino, Corso Torino, ItalyCancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia, Biella, ItalyIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, ItalyImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, ItalyUnit of Molecular Pathology, Biochemistry, and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, ItalyLaboratory of Vascular Cell Biology and Angiogenesis Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, ItalyCancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia, Biella, ItalyReliable liquid biopsy-based tools able to accurately discriminate prostate cancer (PCa) from benign prostatic hyperplasia (BPH), when PSA is within the “gray zone” (PSA 4–10), are still urgent. We analyzed plasma samples from a cohort of 102 consecutively recruited patients with PSA levels between 4 and 16 ng/ml, using the SANIST-Cloud Ion Mobility Metabolomic Mass Spectrometry platform, combined with the analysis of a panel of circulating microRNAs (miR). By coupling CIMS ion mobility technology with SANIST, we were able to reveal three new structures among the most differentially expressed metabolites in PCa vs. BPH. In particular, two were classified as polyunsaturated ceramide ester-like and one as polysaturated glycerol ester-like. Penalized logistic regression was applied to build a model to predict PCa, using six circulating miR, seven circulating metabolites, and demographic/clinical variables, as covariates. Four circulating metabolites, miR-5100, and age were selected by the model, and the corresponding prediction score gave an AUC of 0.76 (C.I. = 0.66–0.85). At a specified cut-off, no high-risk tumor was misclassified, and 22 out of 53 BPH were correctly identified, reducing by 40% the false positives of PSA. We developed and applied a novel, minimally invasive, liquid biopsy-based powerful tool to characterize novel metabolites and identified new potential non-invasive biomarkers to better predict PCa, when PSA is uninformative as a tool for precision medicine in genitourinary cancers.https://www.frontiersin.org/articles/10.3389/fonc.2021.769158/fullSANIST-CIMSceramidemiR-5100prostate cancerbenign prostatic hyperplasialiquid biopsy |
| spellingShingle | Maurizia Mello-Grand Antonino Bruno Lidia Sacchetto Simone Cristoni Ilaria Gregnanin Alessandro Dematteis Andrea Zitella Paolo Gontero Caterina Peraldo-Neia Riccardo Ricotta Douglas M. Noonan Douglas M. Noonan Adriana Albini Giovanna Chiorino Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA Frontiers in Oncology SANIST-CIMS ceramide miR-5100 prostate cancer benign prostatic hyperplasia liquid biopsy |
| title | Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA |
| title_full | Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA |
| title_fullStr | Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA |
| title_full_unstemmed | Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA |
| title_short | Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA |
| title_sort | two novel ceramide like molecules and mir 5100 levels as biomarkers improve prediction of prostate cancer in gray zone psa |
| topic | SANIST-CIMS ceramide miR-5100 prostate cancer benign prostatic hyperplasia liquid biopsy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.769158/full |
| work_keys_str_mv | AT mauriziamellogrand twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT antoninobruno twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT lidiasacchetto twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT simonecristoni twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT ilariagregnanin twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT alessandrodematteis twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT andreazitella twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT paologontero twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT caterinaperaldoneia twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT riccardoricotta twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT douglasmnoonan twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT douglasmnoonan twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT adrianaalbini twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa AT giovannachiorino twonovelceramidelikemoleculesandmir5100levelsasbiomarkersimprovepredictionofprostatecanceringrayzonepsa |